TABLE OF CONTENTS
Volume 74, Issue 5 (November 2003)
Pharmacokinetics and Drug Disposition |
Pharmacogenetics and Genomics |
Clinical Pharmacology Grand Rounds |
Letter to the Editor
Commentaries
American Society for Clinical Pharmacology and Therapeutics position statement on the public health risks of ephedra
Alan S. Hollister MD, PhD and Gregory L. Kearns PharmD, PhD
Clin Pharmacol Ther 74: 403-405; doi:10.1016/S0009-9236(03)00236-4
Label development and the label comprehension study for over-the-counter drugs
Eric P. Brass MD, PhD and Michael Weintraub MD
Clin Pharmacol Ther 74: 406-412; doi:10.1016/S0009-9236(03)00239-X
Pharmacokinetics and Drug Disposition
Impact of ontogeny on linezolid disposition in neonates and infants
Gregory L. Kearns PharmD, PhD, Gail L. Jungbluth PhD, Susan M. Abdel-Rahman PharmD, Nancy K. Hopkins BS, Ian R. Welshman MS, Rosie P. Grzebyk BS, Jon B. Bruss MD, MSPH, John N. van den Anker MD, PhD and The Pediatric Pharmacology Research Unit Network
Clin Pharmacol Ther 74: 413-422; doi:10.1016/S0009-9236(03)00226-1
Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine
Christer Tannergren MSc, Niclas Petri MSc, Lars Knutson MD, PhD, Mikael Hedeland PhD, Ulf Bondesson PhD and Hans Lennernäs PhD
Clin Pharmacol Ther 74: 423-436; doi:10.1016/S0009-9236(03)00238-8
Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail"
Siwaporn Chainuvati MD, Anne N. Nafziger MD, MHS, J. Steven Leeder PharmD, PhD, Andrea Gaedigk PhD, Gregory L. Kearns PharmD, PhD, Edward Sellers MD, PhD, Yanhua Zhang MD, Angela D. M. Kashuba PharmD, Elizabeth Rowland BS and Joseph S. Bertino Jr PharmD
Clin Pharmacol Ther 74: 437-447; doi:10.1016/S0009-9236(03)00229-7
Cytochrome P450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: Correlation with alprazolam pharmacokinetics
Isabella Gashaw PhD, Julia Kirchheiner MD, Mark Goldammer BS, Steffen Bauer PhD, Julia Seidemann BS, Konrad Zoller BS, Przemyslaw M. Mrozikiewicz MD, Ivar Roots MD and Jürgen Brockmöller MD
Clin Pharmacol Ther 74: 448-457; doi:10.1016/S0009-9236(03)00237-6
Impact of serum creatinine measurement error on dose adjustment in renal failure
Verena Schneider MD, Volkmar Henschel PhD, Keyvan Tadjalli-Mehr MD, Ulrich Mansmann PhD and Walter E. Haefeli MD
Clin Pharmacol Ther 74: 458-467; doi:10.1016/S0009-9236(03)00235-2
Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism
Neal L. Benowitz MD, Margaret Peng and Peyton Jacob III PhD
Clin Pharmacol Ther 74: 468-474; doi:10.1016/j.clpt.2003.07.001
The bioavailability of intranasal and smoked methamphetamine
Debra S. Harris MD, Harold Boxenbaum PhD, E. Thomas Everhart PhD, Gina Sequeira MS, John E. Mendelson MD and Reese T. Jones MD
Clin Pharmacol Ther 74: 475-486; doi:10.1016/j.clpt.2003.08.002
Pharmacogenetics and Genomics
No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects
Christiane Pauli-Magnus MD, John Feiner MD, Claire Brett MD, Emil Lin PhD and Deanna L. Kroetz PhD
Clin Pharmacol Ther 74: 487-498; doi:10.1016/S0009-9236(03)00234-0
Venous response to nitroglycerin is enhanced in young, healthy carriers of the 825T allele of the G protein 
3 subunit gene (GNB3)
Anna Mitchell MD, Sandra Bührmann BSc, Anne Seifert, Jens Nürnberger MD, René R. Wenzel MD, Winfried Siffert MD, Thomas Philipp MD and Rafael F. Schäfers MD
Clin Pharmacol Ther 74: 499-504; doi:10.1016/S0009-9236(03)00230-3
Clinical Pharmacology Grand Rounds
Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C9*1/*3 genotype
Shinya Uchida PhD, Hiroshi Watanabe MD, PhD, Shinichiro Nishio MD, Hisakuni Hashimoto PhD, Keisuke Yamazaki MD, Hideharu Hayashi MD, PhD and Kyoichi Ohashi MD, PhD
Clin Pharmacol Ther 74: 505-508; doi:10.1016/j.clpt.2003.08.001
Letter to the Editor
Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches
Albert J. ten Tije MD, Walter J. Loos PhD, Jaap Verweij MD, PhD, Sharyn D. Baker PharmD, Kimberly Dinh PharmD, William D. Figg PharmD and Alex Sparreboom PhD
Clin Pharmacol Ther 74: 509-510; doi:10.1016/j.clpt.2003.08.004
